<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Environ Health Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Environ. Health Perspect</journal-id><journal-title-group><journal-title>Environmental Health Perspectives</journal-title></journal-title-group><issn pub-type="ppub">0091-6765</issn><issn pub-type="epub">1552-9924</issn><publisher><publisher-name>National Institute of Environmental Health Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19165383</article-id><article-id pub-id-type="pmc">2627861</article-id><article-id pub-id-type="doi">10.1289/ehp.11868</article-id><article-id pub-id-type="publisher-id">ehp-117-26</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Effect of Calcium Supplementation on Blood Lead Levels in Pregnancy: A Randomized Placebo-Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ettinger</surname><given-names>Adrienne S.</given-names></name><xref ref-type="aff" rid="af1-ehp-117-26">1</xref><xref ref-type="aff" rid="af2-ehp-117-26">2</xref><xref ref-type="corresp" rid="c1-ehp-117-26"></xref></contrib><contrib contrib-type="author"><name><surname>Lamadrid-Figueroa</surname><given-names>Héctor</given-names></name><xref ref-type="aff" rid="af3-ehp-117-26">3</xref></contrib><contrib contrib-type="author"><name><surname>Téllez-Rojo</surname><given-names>Martha M.</given-names></name><xref ref-type="aff" rid="af3-ehp-117-26">3</xref></contrib><contrib contrib-type="author"><name><surname>Mercado-García</surname><given-names>Adriana</given-names></name><xref ref-type="aff" rid="af3-ehp-117-26">3</xref></contrib><contrib contrib-type="author"><name><surname>Peterson</surname><given-names>Karen E.</given-names></name><xref ref-type="aff" rid="af1-ehp-117-26">1</xref><xref ref-type="aff" rid="af2-ehp-117-26">2</xref></contrib><contrib contrib-type="author"><name><surname>Schwartz</surname><given-names>Joel</given-names></name><xref ref-type="aff" rid="af1-ehp-117-26">1</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Howard</given-names></name><xref ref-type="aff" rid="af1-ehp-117-26">1</xref><xref ref-type="aff" rid="af2-ehp-117-26">2</xref><xref ref-type="aff" rid="af4-ehp-117-26">4</xref></contrib><contrib contrib-type="author"><name><surname>Hernández-Avila</surname><given-names>Mauricio</given-names></name><xref ref-type="aff" rid="af3-ehp-117-26">3</xref><xref ref-type="aff" rid="af5-ehp-117-26">5</xref></contrib></contrib-group><aff id="af1-ehp-117-26"><label>1</label> Harvard School of Public Health, Boston, Massachusetts, USA</aff><aff id="af2-ehp-117-26"><label>2</label> University of Michigan School of Public Health, Ann Arbor, Michigan, USA</aff><aff id="af3-ehp-117-26"><label>3</label> Mexican National Institute of Public Health, Cuernavaca, Morelos, México</aff><aff id="af4-ehp-117-26"><label>4</label> University of Michigan School of Medicine, Ann Arbor, Michigan, USA</aff><aff id="af5-ehp-117-26"><label>5</label> Mexican Ministry of Health, Distrito Federal, México</aff><author-notes><corresp id="c1-ehp-117-26">Address correspondence to A.S. Ettinger, Harvard School of Public Health, Landmark Center West, Room 421, 401 Park Dr., Boston, MA 02215 USA. Telephone: (617) 384-8834. Fax: (617) 384-8745. E-mail:
<email>aettinge@hsph.harvard.edu</email>. Address reprint requests to H. Hu, University of Michigan, Ann Arbor, MI 48109 USA. Telephone: (734) 764-3188. E-mail:
<email>howardhu@umich.edu</email></corresp><fn><p>The authors declare they have no competing financial interests.</p></fn></author-notes><pub-date pub-type="ppub"><month>1</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>2</day><month>9</month><year>2008</year></pub-date><volume>117</volume><issue>1</issue><fpage>26</fpage><lpage>31</lpage><history><date date-type="received"><day>27</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2008</year></date></history><permissions><copyright-year>2009</copyright-year><license xlink:href="http://creativecommons.org/publicdomain/mark/1.0/" license-type="public-domain"><license-p>Publication of EHP lies in the public domain and is therefore without copyright. All text from EHP may be reprinted freely. Use of materials published in EHP should be acknowledged (for example, ?Reproduced with permission from Environmental Health Perspectives?); pertinent reference information should be provided for the article from which the material was reproduced. Articles from EHP, especially the News section, may contain photographs or illustrations copyrighted by other commercial organizations or individuals that may not be used without obtaining prior approval from the holder of the copyright. </license-p></license></permissions><abstract><sec><title><offsets xml_i="5134" xml_f="5144" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5155" xml_f="5392" txt_i="22" txt_f="259">Prenatal lead exposure is associated with deficits in fetal growth and neurodevelopment. Calcium supplementation may attenuate fetal exposure by inhibiting mobilization of maternal bone lead and/or intestinal absorption of ingested lead.</offsets></p></sec><sec><title><offsets xml_i="5414" xml_f="5423" txt_i="261" txt_f="270">Objective</offsets></title><p><offsets xml_i="5434" xml_f="5561" txt_i="271" txt_f="398">Our goal was to evaluate the effect of 1,200 mg dietary calcium supplementation on maternal blood lead levels during pregnancy.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="5602" xml_f="5609" txt_i="400" txt_f="407">Methods</offsets></title><p><offsets xml_i="5620" xml_f="5813" txt_i="408" txt_f="601">In a double-blind, randomized, placebo-controlled trial conducted from 2001 through 2003 in Mexico City, we randomly assigned 670 women in their first trimester of pregnancy to ingest calcium (</offsets><italic><offsets xml_i="5821" xml_f="5822" txt_i="601" txt_f="602">n</offsets></italic><offsets xml_i="5831" xml_f="5851" txt_i="602" txt_f="622"> = 334) or placebo (</offsets><italic><offsets xml_i="5859" xml_f="5860" txt_i="622" txt_f="623">n</offsets></italic><offsets xml_i="5869" xml_f="6223" txt_i="623" txt_f="977"> = 336). We followed subjects through pregnancy and evaluated the effect of supplementation on maternal blood lead, using an intent-to-treat analysis by a mixed-effects regression model with random intercept, in 557 participants (83%) who completed follow-up. We then conducted as-treated analyses using similar models stratified by treatment compliance.</offsets></p></sec><sec><title><offsets xml_i="6245" xml_f="6252" txt_i="979" txt_f="986">Results</offsets></title><p><offsets xml_i="6263" xml_f="6472" txt_i="987" txt_f="1196">Adjusting for baseline lead level, age, trimester of pregnancy, and dietary energy and calcium intake, calcium was associated with an average 11% reduction (0.4 μg/dL) in blood lead level relative to placebo (</offsets><italic><offsets xml_i="6480" xml_f="6481" txt_i="1196" txt_f="1197">p</offsets></italic><offsets xml_i="6490" xml_f="6564" txt_i="1197" txt_f="1271"> = 0.004). This reduction was more evident in the second trimester (−14%, </offsets><italic><offsets xml_i="6572" xml_f="6573" txt_i="1271" txt_f="1272">p</offsets></italic><offsets xml_i="6582" xml_f="6619" txt_i="1272" txt_f="1306"> &lt; 0.001) than in the third (−8%, </offsets><italic><offsets xml_i="6627" xml_f="6628" txt_i="1306" txt_f="1307">p</offsets></italic><offsets xml_i="6637" xml_f="6745" txt_i="1307" txt_f="1415"> = 0.107) and was strongest in women who were most compliant (those who consumed ≥ 75% calcium pills; −24%, </offsets><italic><offsets xml_i="6753" xml_f="6754" txt_i="1415" txt_f="1416">p</offsets></italic><offsets xml_i="6763" xml_f="6821" txt_i="1416" txt_f="1468"> &lt; 0.001), had baseline blood lead &gt; 5 μg/dL (−17%, </offsets><italic><offsets xml_i="6829" xml_f="6830" txt_i="1468" txt_f="1469">p</offsets></italic><offsets xml_i="6839" xml_f="6918" txt_i="1469" txt_f="1545"> &lt; 0.01), or reported use of lead-glazed ceramics and high bone lead (−31%, </offsets><italic><offsets xml_i="6926" xml_f="6927" txt_i="1545" txt_f="1546">p</offsets></italic><offsets xml_i="6936" xml_f="6948" txt_i="1546" txt_f="1555"> &lt; 0.01).</offsets></p></sec><sec><title><offsets xml_i="6970" xml_f="6980" txt_i="1557" txt_f="1567">Conclusion</offsets></title><p><offsets xml_i="6991" xml_f="7232" txt_i="1568" txt_f="1809">Calcium supplementation was associated with modest reductions in blood lead when administered during pregnancy and may constitute an important secondary prevention effort to reduce circulating maternal lead and, consequently, fetal exposure.</offsets></p></sec></abstract><kwd-group><kwd>calcium</kwd><kwd>diet</kwd><kwd>lead</kwd><kwd>pregnancy</kwd><kwd>randomized trial</kwd><kwd>supplementation</kwd></kwd-group></article-meta></front><body><p><offsets xml_i="7429" xml_f="7763" txt_i="1818" txt_f="2152">Despite improvements in environmental policies and significant reductions in average U.S. blood lead levels, lead exposure remains a concern for pregnant and lactating women. This is particularly true among certain population subgroups at increased risk, such as women from developing countries and those with occupational exposures [</offsets><xref rid="b6-ehp-117-26" ref-type="bibr"><offsets xml_i="7805" xml_f="7858" txt_i="2152" txt_f="2205">Centers for Disease Control and Prevention (CDC) 2007</offsets></xref><offsets xml_i="7865" xml_f="7867" txt_i="2205" txt_f="2207">; </offsets><xref rid="b34-ehp-117-26" ref-type="bibr"><offsets xml_i="7910" xml_f="7927" txt_i="2207" txt_f="2224">Meyer et al. 2003</offsets></xref><offsets xml_i="7934" xml_f="8144" txt_i="2224" txt_f="2434">]. In addition, overall declines in environmental sources highlight maternal bone as a long-lived endogenous source of exposure that poses a potential hazard for the developing fetus and breast-feeding infant (</offsets><xref rid="b22-ehp-117-26" ref-type="bibr"><offsets xml_i="8187" xml_f="8214" txt_i="2434" txt_f="2461">Hu and Hernández-Avila 2002</offsets></xref><offsets xml_i="8221" xml_f="8385" txt_i="2461" txt_f="2625">). Redistribution of cumulative maternal bone lead stores into the circulation occurs during periods of increased bone resorption, such as pregnancy and lactation (</offsets><xref rid="b13-ehp-117-26" ref-type="bibr"><offsets xml_i="8428" xml_f="8446" txt_i="2625" txt_f="2643">Gulson et al. 2003</offsets></xref><offsets xml_i="8453" xml_f="8455" txt_i="2643" txt_f="2645">; </offsets><xref rid="b33-ehp-117-26" ref-type="bibr"><offsets xml_i="8498" xml_f="8516" txt_i="2645" txt_f="2663">Manton et al. 2003</offsets></xref><offsets xml_i="8523" xml_f="8525" txt_i="2663" txt_f="2665">; </offsets><xref rid="b41-ehp-117-26" ref-type="bibr"><offsets xml_i="8568" xml_f="8591" txt_i="2665" txt_f="2688">Téllez-Rojo et al. 2004</offsets></xref><offsets xml_i="8598" xml_f="8728" txt_i="2688" txt_f="2818">). Prenatal lead exposure has adverse influences on infant birth and neurodevelopmental outcomes across a wide range of exposure (</offsets><xref rid="b5-ehp-117-26" ref-type="bibr"><offsets xml_i="8770" xml_f="8784" txt_i="2818" txt_f="2832">Bellinger 2005</offsets></xref><offsets xml_i="8791" xml_f="8793" txt_i="2832" txt_f="2834">; </offsets><xref rid="b25-ehp-117-26" ref-type="bibr"><offsets xml_i="8836" xml_f="8850" txt_i="2834" txt_f="2848">Hu et al. 2006</offsets></xref><offsets xml_i="8857" xml_f="8932" txt_i="2848" txt_f="2923">), and maternal bone lead has been shown to be an independent risk factor (</offsets><xref rid="b11-ehp-117-26" ref-type="bibr"><offsets xml_i="8975" xml_f="8992" txt_i="2923" txt_f="2940">Gomaa et al. 2002</offsets></xref><offsets xml_i="8999" xml_f="9001" txt_i="2940" txt_f="2942">; </offsets><xref rid="b12-ehp-117-26" ref-type="bibr"><offsets xml_i="9044" xml_f="9071" txt_i="2942" txt_f="2969">Gonzalez-Cossío et al. 1997</offsets></xref><offsets xml_i="9078" xml_f="9080" txt_i="2969" txt_f="2971">; </offsets><xref rid="b17-ehp-117-26" ref-type="bibr"><offsets xml_i="9123" xml_f="9150" txt_i="2971" txt_f="2998">Hernández-Avila et al. 2002</offsets></xref><offsets xml_i="9157" xml_f="9159" txt_i="2998" txt_f="3000">).</offsets></p><p><offsets xml_i="9166" xml_f="9281" txt_i="3001" txt_f="3116">The potential role of nutrition in altering susceptibility to lead exposure and toxicity has long been recognized (</offsets><xref rid="b2-ehp-117-26" ref-type="bibr"><offsets xml_i="9323" xml_f="9338" txt_i="3116" txt_f="3131">Aub et al. 1932</offsets></xref><offsets xml_i="9345" xml_f="9347" txt_i="3131" txt_f="3133">; </offsets><xref rid="b23-ehp-117-26" ref-type="bibr"><offsets xml_i="9390" xml_f="9404" txt_i="3133" txt_f="3147">Hu et al. 1995</offsets></xref><offsets xml_i="9411" xml_f="9413" txt_i="3147" txt_f="3149">; </offsets><xref rid="b31-ehp-117-26" ref-type="bibr"><offsets xml_i="9456" xml_f="9469" txt_i="3149" txt_f="3162">Mahaffey 1974</offsets></xref><offsets xml_i="9476" xml_f="9478" txt_i="3162" txt_f="3164">, </offsets><xref rid="b32-ehp-117-26" ref-type="bibr"><offsets xml_i="9521" xml_f="9525" txt_i="3164" txt_f="3168">1990</offsets></xref><offsets xml_i="9532" xml_f="9812" txt_i="3168" txt_f="3448">). Dietary intake concurrent to exposure is known to have an impact on lead dynamics, and nutrients may interact with lead by binding lead in the gut, competing with lead for absorption, altering intestinal cell avidity for lead, and altering affinity of target tissues for lead (</offsets><xref rid="b3-ehp-117-26" ref-type="bibr"><offsets xml_i="9854" xml_f="9876" txt_i="3448" txt_f="3470">Ballew and Bowman 2001</offsets></xref><offsets xml_i="9883" xml_f="9885" txt_i="3470" txt_f="3472">).</offsets></p><p><offsets xml_i="9892" xml_f="9967" txt_i="3473" txt_f="3548">Inadequate calcium consumption has been shown to increase lead absorption (</offsets><xref rid="b15-ehp-117-26" ref-type="bibr"><offsets xml_i="10010" xml_f="10036" txt_i="3548" txt_f="3574">Heard and Chamberlain 1982</offsets></xref><offsets xml_i="10043" xml_f="10060" txt_i="3574" txt_f="3591">) and retention (</offsets><xref rid="b39-ehp-117-26" ref-type="bibr"><offsets xml_i="10103" xml_f="10121" txt_i="3591" txt_f="3609">Six and Goyer 1970</offsets></xref><offsets xml_i="10128" xml_f="10252" txt_i="3609" txt_f="3733">). Lead competes with calcium at calcium-binding sites and may subsequently alter protein function and calcium homeostasis (</offsets><xref rid="b38-ehp-117-26" ref-type="bibr"><offsets xml_i="10295" xml_f="10317" txt_i="3733" txt_f="3755">Sauk and Somerman 1991</offsets></xref><offsets xml_i="10324" xml_f="10433" txt_i="3755" txt_f="3864">). Evidence indicates that low dietary calcium and vitamin D are risk factors for elevated bone lead levels (</offsets><xref rid="b7-ehp-117-26" ref-type="bibr"><offsets xml_i="10475" xml_f="10492" txt_i="3864" txt_f="3881">Cheng et al. 1998</offsets></xref><offsets xml_i="10499" xml_f="10635" txt_i="3881" txt_f="4017">). Higher milk intake during pregnancy also has been associated with lower maternal and umbilical cord lead levels in postpartum women (</offsets><xref rid="b19-ehp-117-26" ref-type="bibr"><offsets xml_i="10678" xml_f="10705" txt_i="4017" txt_f="4044">Hernández-Avila et al. 1997</offsets></xref><offsets xml_i="10712" xml_f="10832" txt_i="4044" txt_f="4164">), suggesting that calcium status may be an important factor in the maternal–fetal transfer of lead across the placenta.</offsets></p><p><offsets xml_i="10839" xml_f="11029" txt_i="4165" txt_f="4355">Calcium requirements are increased substantially during pregnancy and lactation in order to meet the needs of the developing fetus and nursing infant for skeletal mineralization and growth (</offsets><xref rid="b36-ehp-117-26" ref-type="bibr"><offsets xml_i="11072" xml_f="11085" txt_i="4355" txt_f="4368">Prentice 2000</offsets></xref><offsets xml_i="11092" xml_f="11254" txt_i="4368" txt_f="4530">). Maternal calcium homeostasis is maintained by controlling intestinal calcium absorption, renal calcium excretion, and mobilization of skeletal mineral stores (</offsets><xref rid="b29-ehp-117-26" ref-type="bibr"><offsets xml_i="11297" xml_f="11323" txt_i="4530" txt_f="4556">Kovacs and Kronenberg 1997</offsets></xref><offsets xml_i="11330" xml_f="11577" txt_i="4556" txt_f="4803">). The role of dietary calcium and mineral adequacy on skeletal changes of pregnancy and lactation is controversial; however, it is recommended that pregnant and breast-feeding women consume 1,000–1,300 mg calcium per day, depending on their age (</offsets><xref rid="b26-ehp-117-26" ref-type="bibr"><offsets xml_i="11620" xml_f="11646" txt_i="4803" txt_f="4829">Institute of Medicine 1997</offsets></xref><offsets xml_i="11653" xml_f="11655" txt_i="4829" txt_f="4831">).</offsets></p><p><offsets xml_i="11662" xml_f="11873" txt_i="4832" txt_f="5043">In a randomized, double-blind, placebo-controlled trial of 1,200 mg daily calcium supplementation in lactating women, we have previously shown that calcium supplementation reduced maternal blood lead by 15–20% (</offsets><xref rid="b16-ehp-117-26" ref-type="bibr"><offsets xml_i="11916" xml_f="11943" txt_i="5043" txt_f="5070">Hernández-Avila et al. 2003</offsets></xref><offsets xml_i="11950" xml_f="11983" txt_i="5070" txt_f="5103">) and breast milk lead by 5–10% (</offsets><xref rid="b10-ehp-117-26" ref-type="bibr"><offsets xml_i="12026" xml_f="12046" txt_i="5103" txt_f="5123">Ettinger et al. 2006</offsets></xref><offsets xml_i="12053" xml_f="12305" txt_i="5123" txt_f="5375">) over the course of lactation. Our objective in the present study was to evaluate the effect of 1,200 mg daily calcium supplementation on maternal blood lead levels during pregnancy, the period of greater relevance for maternal–fetal transfer of lead.</offsets></p><sec sec-type="materials|methods"><title><offsets xml_i="12350" xml_f="12371" txt_i="5376" txt_f="5397">Materials and Methods</offsets></title><sec><title><offsets xml_i="12391" xml_f="12418" txt_i="5398" txt_f="5425">Study population and design</offsets></title><p><offsets xml_i="12429" xml_f="12937" txt_i="5426" txt_f="5934">We recruited pregnant women from 2001 through 2003 at the Mexican Social Security Institute (Instituto Mexicano del Seguro Social) pre-natal clinics that serve a low- to moderate-income population in Mexico City. We assessed 3,836 women for eligibility, of whom 1,981 did not meet study eligibility criteria (pregnancy of no more than 14 weeks’ gestation; not presenting with a high-risk pregnancy; plans to reside in the metropolitan Mexico City area for ~ 5 years) or had other reasons not being enrolled (</offsets><italic><offsets xml_i="12945" xml_f="12946" txt_i="5934" txt_f="5935">n</offsets></italic><offsets xml_i="12955" xml_f="13270" txt_i="5935" txt_f="6250"> = 2). Of the remaining 1,853 eligible women, 670 (36%) agreed to participate and signed the informed consent, and were randomly assigned to receive a daily supplement of 1,200 mg calcium [two 600-mg calcium carbonate tablets (Wyeth Consumer Health Care/Lederle Laboratories, Inc., México City, México) at bedtime; </offsets><italic><offsets xml_i="13278" xml_f="13279" txt_i="6250" txt_f="6251">n</offsets></italic><offsets xml_i="13288" xml_f="13308" txt_i="6251" txt_f="6271"> = 334] or placebo (</offsets><italic><offsets xml_i="13316" xml_f="13317" txt_i="6271" txt_f="6272">n</offsets></italic><offsets xml_i="13326" xml_f="13700" txt_i="6272" txt_f="6646"> = 336). We assessed blood lead levels, dietary calcium intake, and reported use of lead-glazed ceramics (LGC) at three time points: baseline (first trimester), 6 months (second trimester), and 8 months (third trimester). We assessed compliance by pill count at each follow-up visit. We defined women who had at least one blood lead measurement at 6 or 8 months’ gestation (</offsets><italic><offsets xml_i="13708" xml_f="13709" txt_i="6646" txt_f="6647">n</offsets></italic><offsets xml_i="13718" xml_f="13901" txt_i="6647" txt_f="6830"> = 565; 84%) as having completed follow-up. Eight women did not have baseline blood lead levels, yielding a total of 557 subjects (83%) available for inclusion in the final analyses (</offsets><xref ref-type="fig" rid="f1-ehp-117-26"><offsets xml_i="13942" xml_f="13950" txt_i="6830" txt_f="6838">Figure 1</offsets></xref><offsets xml_i="13957" xml_f="13959" txt_i="6838" txt_f="6840">).</offsets></p><p><offsets xml_i="13966" xml_f="14515" txt_i="6841" txt_f="7390">The research protocol was approved by the Human Subjects Committee of the National Institutes of Public Health, the Mexican Social Security Institute, the Brigham and Women’s Hospital, and the Harvard School of Public Health and complied with both Mexican and U.S. federal guidelines governing the use of human participants. All participating mothers received a detailed explanation of the study intent and procedures and were advised on identifying and avoiding LGC pottery use during pregnancy before signing the approved written informed consent.</offsets></p></sec><sec><title><offsets xml_i="14537" xml_f="14559" txt_i="7392" txt_f="7414">Blood lead measurement</offsets></title><p><offsets xml_i="14570" xml_f="14847" txt_i="7415" txt_f="7692">Blood lead measurements(1.0 μg/dL = 0.0483 μmol/L) were performed using graphite furnace atomic absorption spectrophotometry (Perkin-Elmer model 3000; Norwalk, CT, USA) at the American British Cowdray (ABC) Hospital Trace Metal Laboratory according to a technique described in </offsets><xref rid="b35-ehp-117-26" ref-type="bibr"><offsets xml_i="14890" xml_f="14910" txt_i="7692" txt_f="7712">Miller et al. (1987)</offsets></xref><offsets xml_i="14917" xml_f="15145" txt_i="7712" txt_f="7940">. The laboratory participates in the CDC blood lead proficiency testing program administered by the Wisconsin State Laboratory of Hygiene (Madison, WI, USA) and maintained acceptable precision and accuracy over the study period.</offsets></p></sec><sec><title><offsets xml_i="15167" xml_f="15188" txt_i="7942" txt_f="7963">Bone lead measurement</offsets></title><p><offsets xml_i="15199" xml_f="15400" txt_i="7964" txt_f="8165">At 1 month postpartum (± 5 days), maternal bone lead was estimated by a spot-source cadmium-109 K-X-ray fluorescence (K-XRF) instrument at the research facility at the ABC Hospital. We used two 30-min </offsets><italic><offsets xml_i="15408" xml_f="15415" txt_i="8165" txt_f="8172">in vivo</offsets></italic><offsets xml_i="15424" xml_f="15667" txt_i="8172" txt_f="8415"> measurements of each subject’s midtibial shaft (representing cortical bone) and patella (trabecular bone). The physical principles, technical specifications, validation, and use of the K-XRF technique have been described in detail elsewhere (</offsets><xref rid="b8-ehp-117-26" ref-type="bibr"><offsets xml_i="15709" xml_f="15728" txt_i="8415" txt_f="8434">Chettle et al. 2003</offsets></xref><offsets xml_i="15735" xml_f="15737" txt_i="8434" txt_f="8436">; </offsets><xref rid="b24-ehp-117-26" ref-type="bibr"><offsets xml_i="15780" xml_f="15794" txt_i="8436" txt_f="8450">Hu et al. 1998</offsets></xref><offsets xml_i="15801" xml_f="15961" txt_i="8450" txt_f="8607">). For quality control, we excluded bone lead measurements with uncertainty estimates &gt; 10 and 15 μg lead/g mineral bone for tibia and patella, respectively.</offsets></p></sec><sec><title><offsets xml_i="15983" xml_f="15997" txt_i="8609" txt_f="8623">Dietary intake</offsets></title><p><offsets xml_i="16008" xml_f="16385" txt_i="8624" txt_f="9001">We assessed maternal dietary intake in each trimester of pregnancy using a semiquantitative food frequency questionnaire designed to estimate usual dietary intake over the prior month. We based the questionnaire on the semiquantitative food frequency questionnaires and validation methodology used in the Harvard Nurses’ Health Study and Health Professionals’ Follow-up Study (</offsets><xref rid="b43-ehp-117-26" ref-type="bibr"><offsets xml_i="16428" xml_f="16447" txt_i="9001" txt_f="9020">Willett et al. 1985</offsets></xref><offsets xml_i="16454" xml_f="16456" txt_i="9020" txt_f="9022">, </offsets><xref rid="b42-ehp-117-26" ref-type="bibr"><offsets xml_i="16499" xml_f="16503" txt_i="9022" txt_f="9026">1987</offsets></xref><offsets xml_i="16510" xml_f="16634" txt_i="9026" txt_f="9150">). We translated the questionnaire and validated it for use specifically for the Mexican Spanish-speaking adult population (</offsets><xref rid="b18-ehp-117-26" ref-type="bibr"><offsets xml_i="16677" xml_f="16704" txt_i="9150" txt_f="9177">Hernández-Avila et al. 1998</offsets></xref><offsets xml_i="16711" xml_f="16713" txt_i="9177" txt_f="9179">).</offsets></p></sec><sec><title><offsets xml_i="16735" xml_f="16755" txt_i="9181" txt_f="9201">Statistical analysis</offsets></title><p><offsets xml_i="16766" xml_f="16895" txt_i="9202" txt_f="9331">We compared baseline characteristics of participants between the calcium and placebo groups using Wilcoxon ranksum (Mann–Whitney </offsets><italic><offsets xml_i="16903" xml_f="16904" txt_i="9331" txt_f="9332">U</offsets></italic><offsets xml_i="16913" xml_f="16961" txt_i="9332" txt_f="9380">-test) two-sample test of equality or Student’s </offsets><italic><offsets xml_i="16969" xml_f="16970" txt_i="9380" txt_f="9381">t</offsets></italic><offsets xml_i="16979" xml_f="17103" txt_i="9381" txt_f="9505">-test, as appropriate. We performed a similar comparison between those included in the analyses and those lost to follow-up.</offsets></p><p><offsets xml_i="17110" xml_f="18203" txt_i="9506" txt_f="10599">We evaluated the effect of calcium supplement on blood lead concentration using an intent-to-treat analysis by means of a mixed-effects regression model with a random intercept for each subject. This approach takes into account the within-subject correlation structure attributed to the repeated measurements, yielding valid standard errors of the effect estimates. Blood lead concentrations in the second and third trimester of pregnancy were the outcome variables; however, we used models featuring natural-log– transformed blood lead because this parameterization provided the best fit. In order not to exclude very low blood lead concentrations from the analysis, we substituted 27 blood lead measure ments (1.6% of the total) below the limit of detection (1 μg/dL) with random numbers following a uniform distribution between 0 and 1. We adjusted models for the following baseline variables: first trimester log-transformed blood lead concentration, maternal age (years), treatment group, daily calcium (grams per day) and energy intake (kilocalories per day), and trimester of pregnancy.</offsets></p><p><offsets xml_i="18210" xml_f="18390" txt_i="10600" txt_f="10780">To assess the overall intent-to-treat effect of calcium supplementation on blood lead concentrations throughout the last two trimesters of pregnancy, we fitted the following model:</offsets></p><disp-formula><graphic xlink:href="ehp-117-26e1.jpg" position="float"></graphic></disp-formula><p><offsets xml_i="18492" xml_f="18504" txt_i="10781" txt_f="10793">where ln(BPb</offsets><italic><sub><offsets xml_i="18517" xml_f="18520" txt_i="10793" txt_f="10796">i,j</offsets></sub></italic><offsets xml_i="18535" xml_f="18547" txt_i="10796" txt_f="10808">) is the log</offsets><italic><sub><offsets xml_i="18560" xml_f="18561" txt_i="10808" txt_f="10809">e</offsets></sub></italic><offsets xml_i="18576" xml_f="18626" txt_i="10809" txt_f="10859">-transformed blood lead concentration for subject </offsets><italic><offsets xml_i="18634" xml_f="18635" txt_i="10859" txt_f="10860">i</offsets></italic><offsets xml_i="18644" xml_f="18658" txt_i="10860" txt_f="10874"> at trimester </offsets><italic><offsets xml_i="18666" xml_f="18667" txt_i="10874" txt_f="10875">j</offsets></italic><offsets xml_i="18676" xml_f="18682" txt_i="10875" txt_f="10881">, α + </offsets><italic><offsets xml_i="18690" xml_f="18691" txt_i="10881" txt_f="10882">u</offsets></italic><italic><sub><offsets xml_i="18713" xml_f="18714" txt_i="10882" txt_f="10883">i</offsets></sub></italic><offsets xml_i="18729" xml_f="18765" txt_i="10883" txt_f="10919"> denotes the random intercept where </offsets><italic><offsets xml_i="18773" xml_f="18774" txt_i="10919" txt_f="10920">u</offsets></italic><italic><sub><offsets xml_i="18796" xml_f="18797" txt_i="10920" txt_f="10921">i</offsets></sub></italic><offsets xml_i="18812" xml_f="18857" txt_i="10921" txt_f="10966"> represents the error term associated to the </offsets><italic><offsets xml_i="18865" xml_f="18866" txt_i="10966" txt_f="10967">i</offsets></italic><offsets xml_i="18875" xml_f="18887" txt_i="10967" txt_f="10979">th subject [</offsets><italic><offsets xml_i="18895" xml_f="18896" txt_i="10979" txt_f="10980">i</offsets></italic><offsets xml_i="18905" xml_f="18923" txt_i="10980" txt_f="10998"> = (1, 2, . . . , </offsets><italic><offsets xml_i="18931" xml_f="18932" txt_i="10998" txt_f="10999">n</offsets></italic><offsets xml_i="18941" xml_f="18944" txt_i="10999" txt_f="11002">); </offsets><italic><offsets xml_i="18952" xml_f="18953" txt_i="11002" txt_f="11003">u</offsets></italic><italic><sub><offsets xml_i="18975" xml_f="18976" txt_i="11003" txt_f="11004">i</offsets></sub></italic><offsets xml_i="18991" xml_f="18994" txt_i="11004" txt_f="11007"> ~ </offsets><italic><offsets xml_i="19002" xml_f="19003" txt_i="11007" txt_f="11008">n</offsets></italic><offsets xml_i="19012" xml_f="19017" txt_i="11008" txt_f="11013">(0, σ</offsets><sup><offsets xml_i="19022" xml_f="19023" txt_i="11013" txt_f="11014">2</offsets></sup><italic><offsets xml_i="19037" xml_f="19038" txt_i="11014" txt_f="11015">u</offsets></italic><offsets xml_i="19047" xml_f="19051" txt_i="11015" txt_f="11019">)], </offsets><italic><offsets xml_i="19059" xml_f="19060" txt_i="11019" txt_f="11020">S</offsets></italic><italic><sub><offsets xml_i="19082" xml_f="19083" txt_i="11020" txt_f="11021">i</offsets></sub></italic><offsets xml_i="19098" xml_f="19161" txt_i="11021" txt_f="11084"> is a dummy variable that indicates treatment assignment, lnBPb</offsets><italic><sub><offsets xml_i="19174" xml_f="19175" txt_i="11084" txt_f="11085">i</offsets></sub></italic><offsets xml_i="19190" xml_f="19273" txt_i="11085" txt_f="11168"> is the initial (baseline) natural log-transformed blood lead concentration of the </offsets><italic><offsets xml_i="19281" xml_f="19282" txt_i="11168" txt_f="11169">i</offsets></italic><offsets xml_i="19291" xml_f="19303" txt_i="11169" txt_f="11181">th subject, </offsets><italic><offsets xml_i="19311" xml_f="19312" txt_i="11181" txt_f="11182">T</offsets></italic><italic><sub><offsets xml_i="19334" xml_f="19335" txt_i="11182" txt_f="11183">j</offsets></sub></italic><offsets xml_i="19350" xml_f="19358" txt_i="11183" txt_f="11191"> is the </offsets><italic><offsets xml_i="19366" xml_f="19367" txt_i="11191" txt_f="11192">j</offsets></italic><offsets xml_i="19376" xml_f="19403" txt_i="11192" txt_f="11219">th trimester of pregnancy [</offsets><italic><offsets xml_i="19411" xml_f="19412" txt_i="11219" txt_f="11220">j</offsets></italic><offsets xml_i="19421" xml_f="19432" txt_i="11220" txt_f="11231"> = (2,3)], </offsets><italic><offsets xml_i="19440" xml_f="19441" txt_i="11231" txt_f="11232">C</offsets></italic><italic><sub><offsets xml_i="19463" xml_f="19464" txt_i="11232" txt_f="11233">i</offsets></sub></italic><offsets xml_i="19479" xml_f="19517" txt_i="11233" txt_f="11271"> is the baseline daily energy intake, </offsets><italic><offsets xml_i="19525" xml_f="19527" txt_i="11271" txt_f="11273">Ca</offsets></italic><italic><sub><offsets xml_i="19549" xml_f="19550" txt_i="11273" txt_f="11274">i</offsets></sub></italic><offsets xml_i="19565" xml_f="19612" txt_i="11274" txt_f="11321"> is the baseline daily calcium dietary intake, </offsets><italic><offsets xml_i="19620" xml_f="19621" txt_i="11321" txt_f="11322">A</offsets></italic><italic><sub><offsets xml_i="19643" xml_f="19644" txt_i="11322" txt_f="11323">i</offsets></sub></italic><offsets xml_i="19659" xml_f="19673" txt_i="11323" txt_f="11337"> is age, and ɛ</offsets><italic><sub><offsets xml_i="19686" xml_f="19687" txt_i="11337" txt_f="11338">i</offsets></sub></italic><sub><offsets xml_i="19707" xml_f="19708" txt_i="11338" txt_f="11339">,</offsets></sub><italic><sub><offsets xml_i="19727" xml_f="19728" txt_i="11339" txt_f="11340">j</offsets></sub></italic><offsets xml_i="19743" xml_f="19775" txt_i="11340" txt_f="11372"> denotes the random variation [ɛ</offsets><sub><offsets xml_i="19780" xml_f="19783" txt_i="11372" txt_f="11375">i,j</offsets></sub><offsets xml_i="19789" xml_f="19792" txt_i="11375" txt_f="11378"> ~ </offsets><italic><offsets xml_i="19800" xml_f="19801" txt_i="11378" txt_f="11379">n</offsets></italic><offsets xml_i="19810" xml_f="19815" txt_i="11379" txt_f="11384">(0, σ</offsets><sup><offsets xml_i="19820" xml_f="19821" txt_i="11384" txt_f="11385">2</offsets></sup><offsets xml_i="19827" xml_f="19889" txt_i="11385" txt_f="11447">)]. The overall treatment effect estimate is the coefficient β</offsets><sub><offsets xml_i="19894" xml_f="19895" txt_i="11447" txt_f="11448">1</offsets></sub><offsets xml_i="19901" xml_f="19902" txt_i="11448" txt_f="11449">.</offsets></p><p><offsets xml_i="19909" xml_f="19985" txt_i="11450" txt_f="11526">We fitted a second model to estimate the treatment effect at each trimester:</offsets></p><disp-formula><graphic xlink:href="ehp-117-26e2.jpg" position="float"></graphic></disp-formula><p><offsets xml_i="20087" xml_f="20093" txt_i="11527" txt_f="11533">where </offsets><italic><offsets xml_i="20101" xml_f="20102" txt_i="11533" txt_f="11534">S</offsets></italic><italic><sub><offsets xml_i="20124" xml_f="20125" txt_i="11534" txt_f="11535">i</offsets></sub></italic><italic><offsets xml_i="20148" xml_f="20149" txt_i="11535" txt_f="11536">T</offsets></italic><italic><sub><offsets xml_i="20171" xml_f="20172" txt_i="11536" txt_f="11537">j</offsets></sub></italic><offsets xml_i="20187" xml_f="20345" txt_i="11537" txt_f="11695"> denotes the interaction term between blood lead levels and trimester of pregnancy. The treatment effect estimate in the second trimester is the coefficient β</offsets><sub><offsets xml_i="20350" xml_f="20351" txt_i="11695" txt_f="11696">1</offsets></sub><offsets xml_i="20357" xml_f="20402" txt_i="11696" txt_f="11741">, and the effect in the third trimester is (β</offsets><sub><offsets xml_i="20407" xml_f="20408" txt_i="11741" txt_f="11742">1</offsets></sub><offsets xml_i="20414" xml_f="20418" txt_i="11742" txt_f="11746"> + β</offsets><sub><offsets xml_i="20423" xml_f="20424" txt_i="11746" txt_f="11747">7</offsets></sub><offsets xml_i="20430" xml_f="20432" txt_i="11747" txt_f="11749">).</offsets></p><p><offsets xml_i="20439" xml_f="21690" txt_i="11750" txt_f="13001">We used a secondary dose–response study to further assess the effectiveness of supplementation. We assessed compliance by pill count at each visit and analyzed it as proportion of expected pills used between baseline (first trimester) and end of follow-up (8 months’ gestation). We defined treatment compliance group in three ways: ≥ 50% of pills consumed, ≥ 67% of pills consumed, and ≥ 75% of pills consumed. To try to disentangle the effect of calcium supplementation on bone lead mobilization versus gastrointestinal absorption, we developed models with an interaction model for postpartum bone lead levels and reported use of LGC. The rationale for fitting this model was that the effect of the supplement may have been larger in those who had larger bone lead concentration and/ or in those who used LGC. We generated a new dummy variable designating high and low patella bone lead levels dichotomized at the median (5.6 μg/g) and created a two-way interaction term with LGC use (yes/no). We did not include a three-way interaction because we found no reason to think that the magnitude of the effect of bone lead concentrations, and thus bone lead mobilization rates, on blood lead would depend on the use of LGC. We fitted the following model:</offsets></p><disp-formula><graphic xlink:href="ehp-117-26e3.jpg" position="float"></graphic></disp-formula><p><offsets xml_i="21792" xml_f="21800" txt_i="13002" txt_f="13010">where Pb</offsets><italic><sub><offsets xml_i="21813" xml_f="21815" txt_i="13010" txt_f="13012">it</offsets></sub></italic><offsets xml_i="21830" xml_f="21867" txt_i="13012" txt_f="13049"> is blood lead concentration for the </offsets><italic><offsets xml_i="21875" xml_f="21876" txt_i="13049" txt_f="13050">i</offsets></italic><offsets xml_i="21885" xml_f="21903" txt_i="13050" txt_f="13068">th subject at the </offsets><italic><offsets xml_i="21911" xml_f="21912" txt_i="13068" txt_f="13069">t</offsets></italic><offsets xml_i="21921" xml_f="21935" txt_i="13069" txt_f="13083">th trimester, </offsets><italic><offsets xml_i="21943" xml_f="21944" txt_i="13083" txt_f="13084">S</offsets></italic><italic><sub><offsets xml_i="21966" xml_f="21967" txt_i="13084" txt_f="13085">i</offsets></sub></italic><offsets xml_i="21982" xml_f="22013" txt_i="13085" txt_f="13116"> is the supplementation group, </offsets><italic><offsets xml_i="22021" xml_f="22024" txt_i="13116" txt_f="13119">BPb</offsets></italic><italic><sub><offsets xml_i="22046" xml_f="22047" txt_i="13119" txt_f="13120">i</offsets></sub></italic><offsets xml_i="22062" xml_f="22120" txt_i="13120" txt_f="13178"> is the first available postpartum bone lead measurement, </offsets><italic><offsets xml_i="22128" xml_f="22131" txt_i="13178" txt_f="13181">LGC</offsets></italic><italic><sub><offsets xml_i="22153" xml_f="22155" txt_i="13181" txt_f="13183">it</offsets></sub></italic><offsets xml_i="22170" xml_f="22200" txt_i="13183" txt_f="13213"> is current use of LGC in the </offsets><italic><offsets xml_i="22208" xml_f="22209" txt_i="13213" txt_f="13214">i</offsets></italic><offsets xml_i="22218" xml_f="22236" txt_i="13214" txt_f="13232">th subject at the </offsets><italic><offsets xml_i="22244" xml_f="22245" txt_i="13232" txt_f="13233">t</offsets></italic><offsets xml_i="22254" xml_f="22273" txt_i="13233" txt_f="13252">th trimester, and δ</offsets><sub><offsets xml_i="22278" xml_f="22279" txt_i="13252" txt_f="13253">1</offsets></sub><offsets xml_i="22285" xml_f="22405" txt_i="13253" txt_f="13373"> represents the difference in the effect of supplementation between the high and low bone Pb concentration groups, and δ</offsets><sub><offsets xml_i="22410" xml_f="22411" txt_i="13373" txt_f="13374">2</offsets></sub><offsets xml_i="22417" xml_f="22790" txt_i="13374" txt_f="13747"> represents the difference in the effect of supplementation between the current use/ not use of LGC groups. Covariates are baseline blood lead level, baseline daily calcium dietary intake, baseline daily energy intake, age, and trimester of pregnancy. Because we were trying to disentangle biologic mechanisms, we restricted these models to those who with ≥ 75% compliance.</offsets></p><p><offsets xml_i="22797" xml_f="23078" txt_i="13748" txt_f="14026">Finally, to account for possible heterogeneity of treatment effects according to initial blood lead levels, we also performed analysis by baseline blood lead group (&lt; 5 μg/dL vs. ≥ 5 μg/dL) using an intent-to-treat analysis and then among only those women with ≥ 50% compliance.</offsets></p><p><offsets xml_i="23085" xml_f="23201" txt_i="14027" txt_f="14143">We performed all statistical analyses using Stata for Windows (version 9.0; StataCorp LP, College Station, TX, USA).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="23248" xml_f="23255" txt_i="14146" txt_f="14153">Results</offsets></title><p><offsets xml_i="23266" xml_f="23335" txt_i="14154" txt_f="14223">We randomized 670 eligible women to receive calcium supplementation (</offsets><italic><offsets xml_i="23343" xml_f="23344" txt_i="14223" txt_f="14224">n</offsets></italic><offsets xml_i="23353" xml_f="23373" txt_i="14224" txt_f="14244"> = 334) or placebo (</offsets><italic><offsets xml_i="23381" xml_f="23382" txt_i="14244" txt_f="14245">n</offsets></italic><offsets xml_i="23391" xml_f="23400" txt_i="14245" txt_f="14254"> = 336) (</offsets><xref ref-type="fig" rid="f1-ehp-117-26"><offsets xml_i="23441" xml_f="23449" txt_i="14254" txt_f="14262">Figure 1</offsets></xref><offsets xml_i="23456" xml_f="23655" txt_i="14262" txt_f="14461">). Baseline characteristics were largely similar for both the calcium and placebo groups. Mean maternal age was 1 year higher in the control group (26.9 years) than in the calcium group (25.9 years; </offsets><italic><offsets xml_i="23663" xml_f="23664" txt_i="14461" txt_f="14462">p</offsets></italic><offsets xml_i="23673" xml_f="23683" txt_i="14462" txt_f="14472"> = 0.02) (</offsets><xref ref-type="table" rid="t1-ehp-117-26"><offsets xml_i="23726" xml_f="23733" txt_i="14472" txt_f="14479">Table 1</offsets></xref><offsets xml_i="23740" xml_f="24200" txt_i="14479" txt_f="14939">). Approximately 35% of women reported current use of traditional LGC for storing, preparing, or serving food; however, we found no significant differences by treatment group. Dietary calcium intake, also not significantly different between the two groups, was about 900 mg/day on average. Geometric mean (and geometric standard deviation) prerandomization blood lead levels were 3.8 (2.0) and 4.1 (2.0) μg/dL for the calcium and placebo groups, respectively (</offsets><italic><offsets xml_i="24208" xml_f="24209" txt_i="14939" txt_f="14940">p</offsets></italic><offsets xml_i="24218" xml_f="24227" txt_i="14940" txt_f="14949"> = 0.05).</offsets></p><p><offsets xml_i="24234" xml_f="24336" txt_i="14950" txt_f="15052">A total of 565 women (84%) completed follow-up. Comparing the group that completed follow-up (placebo </offsets><italic><offsets xml_i="24344" xml_f="24345" txt_i="15052" txt_f="15053">n</offsets></italic><offsets xml_i="24354" xml_f="24370" txt_i="15053" txt_f="15069"> = 277; calcium </offsets><italic><offsets xml_i="24378" xml_f="24379" txt_i="15069" txt_f="15070">n</offsets></italic><offsets xml_i="24388" xml_f="24434" txt_i="15070" txt_f="15116"> = 288) with those lost to follow-up [placebo </offsets><italic><offsets xml_i="24442" xml_f="24443" txt_i="15116" txt_f="15117">n</offsets></italic><offsets xml_i="24452" xml_f="24473" txt_i="15117" txt_f="15138"> = 59 (18%); calcium </offsets><italic><offsets xml_i="24481" xml_f="24482" txt_i="15138" txt_f="15139">n</offsets></italic><offsets xml_i="24491" xml_f="24572" txt_i="15139" txt_f="15220"> = 46 (14%)], we found no significant differences by treatment group assignment (</offsets><italic><offsets xml_i="24580" xml_f="24581" txt_i="15220" txt_f="15221">p</offsets></italic><offsets xml_i="24590" xml_f="24675" txt_i="15221" txt_f="15306"> = 0.18). Those women who remained in the study reported higher daily energy intake (</offsets><italic><offsets xml_i="24683" xml_f="24684" txt_i="15306" txt_f="15307">p</offsets></italic><offsets xml_i="24693" xml_f="24728" txt_i="15307" txt_f="15339"> &lt; 0.01) and higher use of LGC (</offsets><italic><offsets xml_i="24736" xml_f="24737" txt_i="15339" txt_f="15340">p</offsets></italic><offsets xml_i="24746" xml_f="25012" txt_i="15340" txt_f="15606"> = 0.04) at baseline. Those women who completed follow-up reported higher current use of LGC (36%) than those who did not complete follow-up (26%); among those completing follow-up, however, we found no significant differences in reported LGC use by treatment group.</offsets></p><p><offsets xml_i="25019" xml_f="25052" txt_i="15607" txt_f="15640">In the intent-to-treat analysis (</offsets><italic><offsets xml_i="25060" xml_f="25061" txt_i="15640" txt_f="15641">n</offsets></italic><offsets xml_i="25070" xml_f="25218" txt_i="15641" txt_f="15789"> = 557), calcium supplementation was associated with an overall average reduction of 11% in maternal blood lead concentrations relative to placebo (</offsets><italic><offsets xml_i="25226" xml_f="25227" txt_i="15789" txt_f="15790">p</offsets></italic><offsets xml_i="25236" xml_f="25247" txt_i="15790" txt_f="15801"> = 0.004) (</offsets><xref ref-type="table" rid="t2-ehp-117-26"><offsets xml_i="25290" xml_f="25297" txt_i="15801" txt_f="15808">Table 2</offsets></xref><offsets xml_i="25304" xml_f="25404" txt_i="15808" txt_f="15908">). In a secondary analysis, this reduction was more evident in the second trimester (14% reduction, </offsets><italic><offsets xml_i="25412" xml_f="25413" txt_i="15908" txt_f="15909">p</offsets></italic><offsets xml_i="25422" xml_f="25478" txt_i="15909" txt_f="15962"> &lt; 0.001) than in the third trimester (8% reduction, </offsets><italic><offsets xml_i="25486" xml_f="25487" txt_i="15962" txt_f="15963">p</offsets></italic><offsets xml_i="25496" xml_f="25593" txt_i="15963" txt_f="16060"> = 0.107). These results did not change when we controlled for hematocrit level (data not shown).</offsets></p><p><offsets xml_i="25600" xml_f="25693" txt_i="16061" txt_f="16154">When we assessed the dose–response effect of calcium supplementation for women “as treated” (</offsets><italic><offsets xml_i="25701" xml_f="25702" txt_i="16154" txt_f="16155">n</offsets></italic><offsets xml_i="25711" xml_f="25844" txt_i="16155" txt_f="16288"> = 557) using models stratified by treatment compliance, we saw a clear dose–response effect of calcium on blood lead concentration (</offsets><xref ref-type="table" rid="t3-ehp-117-26"><offsets xml_i="25887" xml_f="25894" txt_i="16288" txt_f="16295">Table 3</offsets></xref><offsets xml_i="25901" xml_f="26063" txt_i="16295" txt_f="16457">). Among those women who consumed ≥ 50% of pills, calcium was associated on average with a 15% reduction in blood lead levels compared with those taking placebo (</offsets><italic><offsets xml_i="26071" xml_f="26072" txt_i="16457" txt_f="16458">p</offsets></italic><offsets xml_i="26081" xml_f="26118" txt_i="16458" txt_f="16492"> &lt; 0.001). This increased to 19% (</offsets><italic><offsets xml_i="26126" xml_f="26127" txt_i="16492" txt_f="16493">p</offsets></italic><offsets xml_i="26136" xml_f="26158" txt_i="16493" txt_f="16512"> &lt; 0.001) and 24% (</offsets><italic><offsets xml_i="26166" xml_f="26167" txt_i="16512" txt_f="16513">p</offsets></italic><offsets xml_i="26176" xml_f="26261" txt_i="16513" txt_f="16595"> &lt; 0.001) for those who consumed ≥ 67% of pills and ≥ 75% of pills, respectively (</offsets><italic><offsets xml_i="26269" xml_f="26270" txt_i="16595" txt_f="16596">p</offsets></italic><offsets xml_i="26279" xml_f="26303" txt_i="16596" txt_f="16617"> for trend &lt; 0.001). </offsets><xref ref-type="fig" rid="f2-ehp-117-26"><offsets xml_i="26344" xml_f="26352" txt_i="16617" txt_f="16625">Figure 2</offsets></xref><offsets xml_i="26359" xml_f="26466" txt_i="16625" txt_f="16732"> shows the effects of calcium and placebo on maternal blood lead over time among the high-compliance group.</offsets></p><p><offsets xml_i="26473" xml_f="26732" txt_i="16733" txt_f="16989">Among the low-compliance group (&lt; 50% of pills consumed), blood lead was higher in the calcium-supplemented group, suggesting that these women were somehow different from the low compliers receiving placebo. In fact, in the group that completed follow-up (</offsets><italic><offsets xml_i="26740" xml_f="26741" txt_i="16989" txt_f="16990">n</offsets></italic><offsets xml_i="26750" xml_f="27052" txt_i="16990" txt_f="17292"> = 565), those with low compliance reported higher current use of LGC in the calcium group (35%) compared with placebo (27%), which might explain the apparent increase in blood lead among the low-compliance group. We found no significant differences in reported LGC use among the high-compliance group.</offsets></p><p><xref ref-type="fig" rid="f3-ehp-117-26"><offsets xml_i="27100" xml_f="27108" txt_i="17293" txt_f="17301">Figure 3</offsets></xref><offsets xml_i="27115" xml_f="27497" txt_i="17301" txt_f="17683"> shows the proportional reduction [and 95% confidence intervals (CIs)] in blood lead due to calcium supplementation, stratified by use of LGC and patella lead level, among the high-compliance group. Among women consuming ≥ 75% of pills, those with high patella bone lead experienced greater reductions than those women with lower bone lead levels, corresponding to a 23% reduction (</offsets><italic><offsets xml_i="27505" xml_f="27506" txt_i="17683" txt_f="17684">p</offsets></italic><offsets xml_i="27515" xml_f="27583" txt_i="17684" txt_f="17752"> = 0.01) for those with no reported use of LGC and a 31% reduction (</offsets><italic><offsets xml_i="27591" xml_f="27592" txt_i="17752" txt_f="17753">p</offsets></italic><offsets xml_i="27601" xml_f="27851" txt_i="17753" txt_f="17997"> &lt; 0.01) for those who reported use of LGC. In this subset of most compliant women with high patella bone lead (&gt; 5 μg/g) and reported use of LGC, the effect corresponds to an average blood lead reduction of 1.95 μg/dL (95% CI, −0.78 to −2.87).</offsets></p><p><offsets xml_i="27858" xml_f="28050" txt_i="17998" txt_f="18187">We repeated the analysis by baseline blood lead group (&lt; 5 μg/dL vs. ≥ 5 μg/dL) using intent-to-treat and as-treated analyses among only those women with compliance ≥50% of pills consumed (</offsets><xref ref-type="table" rid="t4-ehp-117-26"><offsets xml_i="28093" xml_f="28100" txt_i="18187" txt_f="18194">Table 4</offsets></xref><offsets xml_i="28107" xml_f="28567" txt_i="18194" txt_f="18645">). The effects of calcium appeared stronger in the group with higher blood lead at baseline (17% reduction), compared with those with baseline blood lead levels &lt; 5 μg/dL (7% reduction). However, when we restricted the analysis to those women who were more compliant, the reductions were similar between the women with higher (≥ 5 μg/dL = 17%) and lower (&lt; 5 μg/dL = 14%) blood lead at baseline. Among those women with low compliance (&lt; 50% of pills; </offsets><italic><offsets xml_i="28575" xml_f="28576" txt_i="18645" txt_f="18646">n</offsets></italic><offsets xml_i="28585" xml_f="29216" txt_i="18646" txt_f="19274"> = 82), those with low baseline blood lead (&lt; 5 μg/dL) appeared to experience a paradoxical effect of calcium on blood lead levels (an increase of 34%). Those who started the study with higher blood lead (≥ 5 μg/dL) showed the same average effects of treatment (17% reduction), although not statistically significant. Further analysis revealed, however, that the reported use of LGC in low compliers was higher among the calcium group (35%) than in the placebo group (27%), which may account for the apparent differences in treatment effect (7% vs. 17% reduction) observed in the intent-to-treat analysis by baseline blood lead.</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="29260" xml_f="29270" txt_i="19276" txt_f="19286">Discussion</offsets></title><p><offsets xml_i="29281" xml_f="29899" txt_i="19287" txt_f="19899">In this randomized control trial, calcium supplementation (1,200 mg) was associated with modest reductions in blood lead levels when administered during pregnancy. These effects were clearly stronger with increasing compliance, with a 24% average reduction in the most compliant women, and strongest in those with baseline blood lead level &gt; 5 μg/dL (17% average reduction). In the subset of most compliant women with high patella bone lead (&gt; 5 μg/g) and reported use of LGC, we found the greatest reduction in blood lead of 31%, which corresponds to an average reduction of 1.95 μg/dL (95% CI, −0.78 to −2.87).</offsets></p><p><offsets xml_i="29906" xml_f="30124" txt_i="19900" txt_f="20118">These results are consistent with our previously published randomized trial, which showed that dietary calcium supplementation among postpartum women reduced maternal blood lead by 15–20% over the course of lactation (</offsets><xref rid="b16-ehp-117-26" ref-type="bibr"><offsets xml_i="30167" xml_f="30194" txt_i="20118" txt_f="20145">Hernández-Avila et al. 2003</offsets></xref><offsets xml_i="30201" xml_f="30460" txt_i="20145" txt_f="20401">). In that study, the effect among women who were compliant with supplement use (≥ 50% of pills consumed) and had high bone lead (patella lead &gt; 5 μg lead/g bone mineral) was an estimated reduction in mean blood lead of 1.16 μg/dL (95% CI, −2.08 to −0.23).</offsets></p><p><offsets xml_i="30467" xml_f="30532" txt_i="20402" txt_f="20467">These results are also consistent with the results of a study by </offsets><xref rid="b14-ehp-117-26" ref-type="bibr"><offsets xml_i="30575" xml_f="30595" txt_i="20467" txt_f="20487">Gulson et al. (2004)</offsets></xref><offsets xml_i="30602" xml_f="31064" txt_i="20487" txt_f="20949"> of blood lead isotopic ratios during pregnancy among women who had recently immigrated to Australia. The authors found that compared with an earlier group of such women they had studied who had calcium-deficient diets, calcium-replete women had a rise in blood lead levels during pregnancy (with an isotopic fingerprint suggesting the lead came from bone) that occurred later in pregnancy and of a smaller magnitude. Although the use of lead isotopic ratios by </offsets><xref rid="b14-ehp-117-26" ref-type="bibr"><offsets xml_i="31107" xml_f="31127" txt_i="20949" txt_f="20969">Gulson et al. (2004)</offsets></xref><offsets xml_i="31134" xml_f="31390" txt_i="20969" txt_f="21222"> provided very rigorous and precise methodology to their work, the interpretation with respect to calcium supplementation is limited by the small number of women (&lt; 20) in their cases series [and thus limited statistical power to detect an association (</offsets><xref rid="b1-ehp-117-26" ref-type="bibr"><offsets xml_i="31432" xml_f="31453" txt_i="21222" txt_f="21243">Altman and Bland 1995</offsets></xref></p><p><offsets xml_i="31467" xml_f="31802" txt_i="21244" txt_f="21579">The effect of calcium may be exerted, at least in part, by decreasing bone resorption and the consequent mobilization of maternal bone lead stores. In a case–crossover trial of calcium supplementation during the third trimester of pregnancy, we have previously shown that maternal bone resorption, as reflected by urinary cross-linked </offsets><italic><offsets xml_i="31810" xml_f="31811" txt_i="21579" txt_f="21580">N</offsets></italic><offsets xml_i="31820" xml_f="31940" txt_i="21580" txt_f="21700">-telopeptide, was reduced by an average of 13.6 nM bone collagen equivalents/mM creatinine (14%) compared with placebo (</offsets><xref rid="b27-ehp-117-26" ref-type="bibr"><offsets xml_i="31983" xml_f="32006" txt_i="21700" txt_f="21723">Janakiraman et al. 2003</offsets></xref><offsets xml_i="32013" xml_f="32096" txt_i="21723" txt_f="21806">), indicating that calcium supplementation can suppress maternal bone mobilization.</offsets></p><p><offsets xml_i="32103" xml_f="32714" txt_i="21807" txt_f="22418">The effects of calcium may also be attributed to decreasing the intestinal absorption of lead and/or increasing the excretion of lead from circulation. In the present study, we did not have prepregnancy bone lead levels, and Mexican laws forbidding potential radiation exposure during pregnancy did not allow us to obtain bone lead measurements during pregnancy. However, our observation in the stratum of women with no reported LGC use—that the calcium effect is greater in those with high bone lead—suggests that, in this population, the effect may have been exerted mainly through inhibiting bone resorption.</offsets></p><p><offsets xml_i="32721" xml_f="32908" txt_i="22419" txt_f="22606">Average baseline dietary calcium intake for women in our trials of Mexican women was less than the U.S. recommended dietary intake of 1,000–1,300 mg/day for pregnant and lactating women (</offsets><xref rid="b26-ehp-117-26" ref-type="bibr"><offsets xml_i="32951" xml_f="32977" txt_i="22606" txt_f="22632">Institute of Medicine 1997</offsets></xref><offsets xml_i="32984" xml_f="33123" txt_i="22632" txt_f="22771">). Levels of dietary calcium intake in our studies were, however, consistent with those reported in the Mexican National Nutrition Survey (</offsets><xref rid="b4-ehp-117-26" ref-type="bibr"><offsets xml_i="33165" xml_f="33185" txt_i="22771" txt_f="22791">Barquera et al. 2003</offsets></xref><offsets xml_i="33192" xml_f="33272" txt_i="22791" txt_f="22871">) and in a nationally representative sample of U.S. women of child-bearing age (</offsets><xref rid="b30-ehp-117-26" ref-type="bibr"><offsets xml_i="33315" xml_f="33330" txt_i="22871" txt_f="22886">Lee et al. 2005</offsets></xref><offsets xml_i="33337" xml_f="33340" txt_i="22886" txt_f="22889">). </offsets><xref rid="b20-ehp-117-26" ref-type="bibr"><offsets xml_i="33383" xml_f="33412" txt_i="22889" txt_f="22918">Hertz-Picciotto et al. (2000)</offsets></xref><offsets xml_i="33419" xml_f="33904" txt_i="22918" txt_f="23403"> followed 195 women over the course of pregnancy and found a U-shaped pattern of maternal blood lead concentration across pregnancy. The late pregnancy increases were steeper among women with low dietary calcium intake in both the low and high age groups, suggesting that lead redistribution may be more pronounced among pregnant women in calcium-deficient states. It is possible that high amounts of calcium are needed to counterbalance the nutritional needs of the developing fetus (</offsets><xref rid="b28-ehp-117-26" ref-type="bibr"><offsets xml_i="33947" xml_f="33959" txt_i="23403" txt_f="23415">Johnson 2001</offsets></xref><offsets xml_i="33966" xml_f="34037" txt_i="23415" txt_f="23486">). Other genetic, hormonal, or lifestyle factors may also be involved (</offsets><xref rid="b9-ehp-117-26" ref-type="bibr"><offsets xml_i="34079" xml_f="34099" txt_i="23486" txt_f="23506">Ettinger et al. 2007</offsets></xref><offsets xml_i="34106" xml_f="34108" txt_i="23506" txt_f="23508">).</offsets></p><p><offsets xml_i="34115" xml_f="34484" txt_i="23509" txt_f="23878">Nonetheless, dietary calcium intake likely plays a limited, but still important, role in suppressing mobilization of lead from maternal bone and/or decreasing gastrointestinal absorption of ingested lead, thereby decreasing the risk of fetal and infant exposure. Calcium supplementation during pregnancy may also reduce the risk of hypertensive disorders of pregnancy (</offsets><xref rid="b21-ehp-117-26" ref-type="bibr"><offsets xml_i="34527" xml_f="34546" txt_i="23878" txt_f="23897">Hofmeyr et al. 2007</offsets></xref><offsets xml_i="34553" xml_f="34603" txt_i="23897" txt_f="23947">) that may also arise secondary to lead exposure (</offsets><xref rid="b37-ehp-117-26" ref-type="bibr"><offsets xml_i="34646" xml_f="34668" txt_i="23947" txt_f="23969">Rothenberg et al. 2002</offsets></xref><offsets xml_i="34675" xml_f="34677" txt_i="23969" txt_f="23971">; </offsets><xref rid="b40-ehp-117-26" ref-type="bibr"><offsets xml_i="34720" xml_f="34738" txt_i="23971" txt_f="23989">Sowers et al. 2002</offsets></xref><offsets xml_i="34745" xml_f="35440" txt_i="23989" txt_f="24684">) (and thus conferring additional negative effects of lead for both mother and fetus and a potential benefit of calcium supplementation). The risks posed by calcium supplementation at levels approximating recommended daily intakes in this population are negligible. We therefore conclude that dietary supplementation of calcium intake should be considered as a cost-effective means for lowering transgenerational fetal lead exposure. This is particularly important in populations where dietary calcium intake is low. Because bone lead has a half-life of years to decades, women and their infants will continue to be at risk for exposure long after environmental sources of lead have been abated.</offsets></p></sec></body><back><fn-group><fn><p>We thank the American British Cowdray Hospital in Mexico City for the use of their research facilities.</p></fn><fn><p>This study was supported by the U.S. National Institute of Environmental Health Sciences (NIEHS) grants P42-ES05947, R01-ES07821, R01-ES014930, P30-ES00002, and K23-ES000381; by Consejo Nacional de Ciencia y Tecnología (CONACyT) grant 4150M9405; and by Consejo de Estudios para la Restauración y Valoración Ambiental (CONSERVA), Department of Federal District, México. A.S.E. was supported by NIEHS K01-ES014907-01A1.</p></fn><fn><p>The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS or the National Institutes of Health.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Bland</surname><given-names>JM</given-names></name></person-group><year>1995</year><article-title>Absence of evidence is not evidence of absence</article-title><source>BMJ</source><volume>311</volume><issue>7003</issue><fpage>485</fpage><pub-id pub-id-type="pmid">7647644</pub-id></element-citation></ref><ref id="b2-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aub</surname><given-names>JC</given-names></name><name><surname>Robb</surname><given-names>GP</given-names></name><name><surname>Rossmeisl</surname><given-names>E</given-names></name></person-group><year>1932</year><article-title>Significance of bone trabeculae in the treatment of lead poisoning: lead studies XVII</article-title><source>Am J Public Health Nations Health</source><volume>22</volume><issue>8</issue><fpage>825</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">18013560</pub-id></element-citation></ref><ref id="b3-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballew</surname><given-names>C</given-names></name><name><surname>Bowman</surname><given-names>B</given-names></name></person-group><year>2001</year><article-title>Recommending calcium to reduce lead toxicity in children: a critical review</article-title><source>Nutr Rev</source><volume>59</volume><issue>3 pt 1</issue><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11330624</pub-id></element-citation></ref><ref id="b4-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barquera</surname><given-names>S</given-names></name><name><surname>Rivera</surname><given-names>JA</given-names></name><name><surname>Espinosa-Montero</surname><given-names>J</given-names></name><name><surname>Safdie</surname><given-names>M</given-names></name><name><surname>Campirano</surname><given-names>F</given-names></name><name><surname>Monterrubio</surname><given-names>EA</given-names></name></person-group><year>2003</year><article-title>Energy and nutrient consumption in Mexican women 12–49 years of age: analysis of the National Nutrition Survey 1999</article-title><source>Salud Publica Mex</source><volume>45</volume><issue>suppl 4</issue><fpage>S530</fpage><lpage>S539</lpage><pub-id pub-id-type="pmid">14746047</pub-id></element-citation></ref><ref id="b5-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellinger</surname><given-names>DC</given-names></name></person-group><year>2005</year><article-title>Teratogen update: lead and pregnancy</article-title><source>Birth Defects Res A Clin Mol Teratol</source><volume>73</volume><issue>6</issue><fpage>409</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">15880700</pub-id></element-citation></ref><ref id="b6-ehp-117-26"><element-citation publication-type="journal"><collab>CDC (Centers for Disease Control and Prevention)</collab><year>2007</year><article-title>Lead exposure among females of childbearing age—United States, 2004</article-title><source>MMWR Morb Mortal Wkly Rep</source><volume>56</volume><issue>16</issue><fpage>397</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">17464282</pub-id></element-citation></ref><ref id="b7-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Sparrow</surname><given-names>D</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name></person-group><year>1998</year><article-title>Relation of nutrition to bone lead and blood lead levels in middle-aged to elderly men. The Normative Aging Study</article-title><source>Am J Epidemiol</source><volume>147</volume><issue>12</issue><fpage>1162</fpage><lpage>1174</lpage><pub-id pub-id-type="pmid">9645795</pub-id></element-citation></ref><ref id="b8-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chettle</surname><given-names>DR</given-names></name><name><surname>Arnold</surname><given-names>ML</given-names></name><name><surname>Aro</surname><given-names>AC</given-names></name><name><surname>Fleming</surname><given-names>DE</given-names></name><name><surname>Kondrashov</surname><given-names>VS</given-names></name><name><surname>McNeill</surname><given-names>FE</given-names></name><etal></etal></person-group><year>2003</year><article-title>An agreed statement on calculating lead concentration and uncertainty in XRF <italic>in vivo</italic> bone lead analysis</article-title><source>Appl Radiat Isot</source><volume>58</volume><issue>5</issue><fpage>603</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">12735978</pub-id></element-citation></ref><ref id="b9-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ettinger</surname><given-names>AS</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Hernández-Avila</surname><given-names>M</given-names></name></person-group><year>2007</year><article-title>Dietary calcium supplementation to lower blood lead levels in pregnancy and lactation</article-title><source>J Nutr Biochem</source><volume>18</volume><issue>3</issue><fpage>172</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">17296490</pub-id></element-citation></ref><ref id="b10-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ettinger</surname><given-names>AS</given-names></name><name><surname>Téllez-Rojo</surname><given-names>MM</given-names></name><name><surname>Amarasiriwardena</surname><given-names>C</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Aro</surname><given-names>A</given-names></name><etal></etal></person-group><year>2006</year><article-title>Influence of maternal bone lead burden and calcium intake on levels of lead in breast milk over the course of lactation</article-title><source>Am J Epidemiol</source><volume>163</volume><issue>1</issue><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">16282237</pub-id></element-citation></ref><ref id="b11-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomaa</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Bellinger</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>J</given-names></name><name><surname>Tsaih</surname><given-names>SW</given-names></name><name><surname>Gonzalez-Cossío</surname><given-names>T</given-names></name><etal></etal></person-group><year>2002</year><article-title>Maternal bone lead as an independent risk factor for fetal neurotoxicity: a prospective study</article-title><source>Pediatrics</source><volume>110</volume><issue>1 pt 1</issue><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">12093955</pub-id></element-citation></ref><ref id="b12-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Cossío</surname><given-names>T</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name><name><surname>Sanin</surname><given-names>LH</given-names></name><name><surname>Fishbein</surname><given-names>E</given-names></name><name><surname>Palazuelos</surname><given-names>E</given-names></name><name><surname>Aro</surname><given-names>A</given-names></name><etal></etal></person-group><year>1997</year><article-title>Decrease in birth weight in relation to maternal bone-lead burden</article-title><source>Pediatrics</source><volume>100</volume><issue>5</issue><fpage>856</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">9346987</pub-id></element-citation></ref><ref id="b13-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulson</surname><given-names>BL</given-names></name><name><surname>Mizon</surname><given-names>KJ</given-names></name><name><surname>Korsch</surname><given-names>MJ</given-names></name><name><surname>Palmer</surname><given-names>JM</given-names></name><name><surname>Donnelly</surname><given-names>JB</given-names></name></person-group><year>2003</year><article-title>Mobilization of lead from human bone tissue during pregnancy and lactation—a summary of long-term research</article-title><source>Sci Total Environ</source><volume>303</volume><issue>1–2</issue><fpage>79</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">12568766</pub-id></element-citation></ref><ref id="b14-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulson</surname><given-names>BL</given-names></name><name><surname>Mizon</surname><given-names>KJ</given-names></name><name><surname>Palmer</surname><given-names>JM</given-names></name><name><surname>Korsch</surname><given-names>MJ</given-names></name><name><surname>Taylor</surname><given-names>AJ</given-names></name><name><surname>Mahaffey</surname><given-names>KR</given-names></name></person-group><year>2004</year><article-title>Blood lead changes during pregnancy and postpartum with calcium supplementation</article-title><source>Environ Health Perspect</source><volume>112</volume><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="pmid">15531434</pub-id></element-citation></ref><ref id="b15-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heard</surname><given-names>MJ</given-names></name><name><surname>Chamberlain</surname><given-names>AC</given-names></name></person-group><year>1982</year><article-title>Effect of minerals and food on uptake of lead from the gastrointestinal tract in humans</article-title><source>Hum Toxicol</source><volume>1</volume><issue>4</issue><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">7173926</pub-id></element-citation></ref><ref id="b16-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Avila</surname><given-names>M</given-names></name><name><surname>Gonzalez-Cossío</surname><given-names>T</given-names></name><name><surname>Hernández-Avila</surname><given-names>JE</given-names></name><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name><name><surname>Aro</surname><given-names>A</given-names></name><etal></etal></person-group><year>2003</year><article-title>Dietary calcium supplements to lower blood lead levels in lactating women: a randomized placebo-controlled trial</article-title><source>Epidemiology</source><volume>14</volume><issue>2</issue><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">12606887</pub-id></element-citation></ref><ref id="b17-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Avila</surname><given-names>M</given-names></name><name><surname>Peterson</surname><given-names>KE</given-names></name><name><surname>Gonzalez-Cossío</surname><given-names>T</given-names></name><name><surname>Sanin</surname><given-names>LH</given-names></name><name><surname>Aro</surname><given-names>A</given-names></name><name><surname>Schnaas</surname><given-names>L</given-names></name><etal></etal></person-group><year>2002</year><article-title>Effect of maternal bone lead on length and head circumference of newborns and 1-month-old infants</article-title><source>Arch Environ Health</source><volume>57</volume><issue>5</issue><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">12641193</pub-id></element-citation></ref><ref id="b18-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Avila</surname><given-names>M</given-names></name><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Parra</surname><given-names>S</given-names></name><name><surname>Hernández-Avila</surname><given-names>J</given-names></name><name><surname>Madrigal</surname><given-names>H</given-names></name><name><surname>Willett</surname><given-names>W</given-names></name></person-group><year>1998</year><article-title>Validity and reproducibility of a food frequency questionnaire to assess dietary intake of women living in Mexico City</article-title><source>Salud Publica Mex</source><volume>40</volume><issue>2</issue><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">9617194</pub-id></element-citation></ref><ref id="b19-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Avila</surname><given-names>M</given-names></name><name><surname>Sanin</surname><given-names>LH</given-names></name><name><surname>Romieu</surname><given-names>I</given-names></name><name><surname>Palazuelos</surname><given-names>E</given-names></name><name><surname>Tapia-Conyer</surname><given-names>R</given-names></name><name><surname>Olaiz</surname><given-names>G</given-names></name><etal></etal></person-group><year>1997</year><article-title>Higher milk intake during pregnancy is associated with lower maternal and umbilical cord lead levels in postpartum women</article-title><source>Environ Res</source><volume>74</volume><issue>2</issue><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">9339224</pub-id></element-citation></ref><ref id="b20-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertz-Picciotto</surname><given-names>I</given-names></name><name><surname>Schramm</surname><given-names>M</given-names></name><name><surname>Watt-Morse</surname><given-names>M</given-names></name><name><surname>Chantala</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Osterloh</surname><given-names>J</given-names></name></person-group><year>2000</year><article-title>Patterns and determinants of blood lead during pregnancy</article-title><source>Am J Epidemiol</source><volume>152</volume><issue>9</issue><fpage>829</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">11085394</pub-id></element-citation></ref><ref id="b21-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmeyr</surname><given-names>GJ</given-names></name><name><surname>Duley</surname><given-names>L</given-names></name><name><surname>Atallah</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>Dietary calcium supplementation for prevention of pre-eclampsia and related problems: a systematic review and commentary</article-title><source>BJOG</source><volume>114</volume><issue>8</issue><fpage>933</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">17565614</pub-id></element-citation></ref><ref id="b22-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Hernández-Avila</surname><given-names>M</given-names></name></person-group><year>2002</year><article-title>Invited commentary: lead, bones, women, and pregnancy—the poison within?</article-title><source>Am J Epidemiol</source><volume>156</volume><issue>12</issue><fpage>1088</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">12480652</pub-id></element-citation></ref><ref id="b23-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Kotha</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>T</given-names></name></person-group><year>1995</year><article-title>The role of nutrition in mitigating environmental insults: policy and ethical issues</article-title><source>Environ Health Perspect</source><volume>103</volume><issue>suppl 6</issue><fpage>185</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">8549471</pub-id></element-citation></ref><ref id="b24-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Rabinowitz</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name></person-group><year>1998</year><article-title>Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms</article-title><source>Environ Health Perspect</source><volume>106</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9417769</pub-id></element-citation></ref><ref id="b25-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Téllez-Rojo</surname><given-names>MM</given-names></name><name><surname>Bellinger</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Ettinger</surname><given-names>AS</given-names></name><name><surname>Lamadrid-Figueroa</surname><given-names>H</given-names></name><etal></etal></person-group><year>2006</year><article-title>Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development</article-title><source>Environ Health Perspect</source><volume>114</volume><fpage>1730</fpage><lpage>1735</lpage><pub-id pub-id-type="pmid">17107860</pub-id></element-citation></ref><ref id="b26-ehp-117-26"><element-citation publication-type="book"><collab>Institute of Medicine</collab><year>1997</year><source>Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride</source><publisher-loc>Washington, DC</publisher-loc><publisher-name>National Academy Press</publisher-name></element-citation></ref><ref id="b27-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janakiraman</surname><given-names>V</given-names></name><name><surname>Ettinger</surname><given-names>A</given-names></name><name><surname>Mercado-García</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Hernández-Avila</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>Calcium supplements and bone resorption in pregnancy: a randomized crossover trial</article-title><source>Am J Prev Med</source><volume>24</volume><issue>3</issue><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">12657345</pub-id></element-citation></ref><ref id="b28-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>MA</given-names></name></person-group><year>2001</year><article-title>High calcium intake blunts pregnancy-induced increases in maternal blood lead</article-title><source>Nutr Rev</source><volume>59</volume><issue>5</issue><fpage>152</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">11396696</pub-id></element-citation></ref><ref id="b29-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>CS</given-names></name><name><surname>Kronenberg</surname><given-names>HM</given-names></name></person-group><year>1997</year><article-title>Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation</article-title><source>Endocr Rev</source><volume>18</volume><issue>6</issue><fpage>832</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">9408745</pub-id></element-citation></ref><ref id="b30-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MG</given-names></name><name><surname>Chun</surname><given-names>OK</given-names></name><name><surname>Song</surname><given-names>WO</given-names></name></person-group><year>2005</year><article-title>Determinants of the blood lead level of US women of reproductive age</article-title><source>J Am Coll Nutr</source><volume>24</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15670978</pub-id></element-citation></ref><ref id="b31-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahaffey</surname><given-names>KR</given-names></name></person-group><year>1974</year><article-title>Nutritional factors and susceptibility to lead toxicity</article-title><source>Environ Health Perspect</source><volume>7</volume><fpage>107</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">4831135</pub-id></element-citation></ref><ref id="b32-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahaffey</surname><given-names>KR</given-names></name></person-group><year>1990</year><article-title>Environmental lead toxicity: nutrition as a component of intervention</article-title><source>Environ Health Perspect</source><volume>89</volume><fpage>75</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">2088758</pub-id></element-citation></ref><ref id="b33-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manton</surname><given-names>WI</given-names></name><name><surname>Angle</surname><given-names>CR</given-names></name><name><surname>Stanek</surname><given-names>KL</given-names></name><name><surname>Kuntzelman</surname><given-names>D</given-names></name><name><surname>Reese</surname><given-names>YR</given-names></name><name><surname>Kuehnemann</surname><given-names>TJ</given-names></name></person-group><year>2003</year><article-title>Release of lead from bone in pregnancy and lactation</article-title><source>Environ Res</source><volume>92</volume><issue>2</issue><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">12854694</pub-id></element-citation></ref><ref id="b34-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>PA</given-names></name><name><surname>McGeehin</surname><given-names>MA</given-names></name><name><surname>Falk</surname><given-names>H</given-names></name></person-group><year>2003</year><article-title>A global approach to childhood lead poisoning prevention</article-title><source>Int J Hyg Environ Health</source><volume>206</volume><issue>4–5</issue><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">12971691</pub-id></element-citation></ref><ref id="b35-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DT</given-names></name><name><surname>Paschal</surname><given-names>DC</given-names></name><name><surname>Gunter</surname><given-names>EW</given-names></name><name><surname>Stroud</surname><given-names>PE</given-names></name><name><surname>D’Angelo</surname><given-names>J</given-names></name></person-group><year>1987</year><article-title>Determination of lead in blood using electrothermal atomisation atomic absorption spectrometry with a L’vov platform and matrix modifier</article-title><source>Analyst</source><volume>112</volume><issue>12</issue><fpage>1701</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">3445938</pub-id></element-citation></ref><ref id="b36-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prentice</surname><given-names>A</given-names></name></person-group><year>2000</year><article-title>Calcium in pregnancy and lactation</article-title><source>Annu Rev Nutr</source><volume>20</volume><fpage>249</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">10940334</pub-id></element-citation></ref><ref id="b37-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>SJ</given-names></name><name><surname>Kondrashov</surname><given-names>V</given-names></name><name><surname>Manalo</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Cuellar</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><etal></etal></person-group><year>2002</year><article-title>Increases in hypertension and blood pressure during pregnancy with increased bone lead levels</article-title><source>Am J Epidemiol</source><volume>156</volume><issue>12</issue><fpage>1079</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">12480651</pub-id></element-citation></ref><ref id="b38-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauk</surname><given-names>JJ</given-names></name><name><surname>Somerman</surname><given-names>MJ</given-names></name></person-group><year>1991</year><article-title>Physiology of bone: mineral compartment proteins as candidates for environmental perturbation by lead</article-title><source>Environ Health Perspect</source><volume>91</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">2040255</pub-id></element-citation></ref><ref id="b39-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Six</surname><given-names>KM</given-names></name><name><surname>Goyer</surname><given-names>RA</given-names></name></person-group><year>1970</year><article-title>Experimental enhancement of lead toxicity by low dietary calcium</article-title><source>J Lab Clin Med</source><volume>76</volume><issue>6</issue><fpage>933</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">5485382</pub-id></element-citation></ref><ref id="b40-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sowers</surname><given-names>M</given-names></name><name><surname>Jannausch</surname><given-names>M</given-names></name><name><surname>Scholl</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Kemp</surname><given-names>FW</given-names></name><name><surname>Bogden</surname><given-names>JD</given-names></name></person-group><year>2002</year><article-title>Blood lead concentrations and pregnancy outcomes</article-title><source>Arch Environ Health</source><volume>57</volume><issue>5</issue><fpage>489</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">12641194</pub-id></element-citation></ref><ref id="b41-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Téllez-Rojo</surname><given-names>MM</given-names></name><name><surname>Hernández-Avila</surname><given-names></given-names></name><name><surname>Lamadrid-Figueroa</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Hernández-Cadena</surname><given-names>L</given-names></name><name><surname>Mercado</surname><given-names>A</given-names></name><etal></etal></person-group><year>2004</year><article-title>Impact of bone lead and bone resorption on plasma and whole blood lead levels during pregnancy</article-title><source>Am J Epidemiol</source><volume>160</volume><issue>7</issue><fpage>668</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">15383411</pub-id></element-citation></ref><ref id="b42-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Reynolds</surname><given-names>RD</given-names></name><name><surname>Cottrell-Hoehner</surname><given-names>S</given-names></name><name><surname>Sampson</surname><given-names>L</given-names></name><name><surname>Browne</surname><given-names>ML</given-names></name></person-group><year>1987</year><article-title>Validation of a semi-quantitative food frequency questionnaire: comparison with a 1-year diet record</article-title><source>J Am Diet Assoc</source><volume>87</volume><issue>1</issue><fpage>43</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">3794132</pub-id></element-citation></ref><ref id="b43-ehp-117-26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willett</surname><given-names>WC</given-names></name><name><surname>Sampson</surname><given-names>L</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Rosner</surname><given-names>B</given-names></name><name><surname>Bain</surname><given-names>C</given-names></name><name><surname>Witschi</surname><given-names>J</given-names></name><etal></etal></person-group><year>1985</year><article-title>Reproducibility and validity of a semiquantitative food frequency questionnaire</article-title><source>Am J Epidemiol</source><volume>122</volume><issue>1</issue><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">4014201</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ehp-117-26" position="float"><label>Figure 1</label><caption><p>Study sample profile.</p></caption><graphic xlink:href="ehp-117-26f1"></graphic></fig><fig id="f2-ehp-117-26" position="float"><label>Figure 2</label><caption><p>Effect of calcium supplementation on maternal blood lead at each trimester during pregnancy among the high-compliance group (≥ 75% of pills by pill count, adjusting for baseline blood lead, age, dietary calcium intake, and daily energy intake.</p></caption><graphic xlink:href="ehp-117-26f2"></graphic></fig><fig id="f3-ehp-117-26" position="float"><label>Figure 3</label><caption><p>Blood lead proportional reduction estimates due to calcium supplementation (and 95% CIs), stratified by use of LGC (yes/no) and bone lead level (high/low) among the high-compliance group (≥ 75% of pills by pill count, adjusting for baseline blood lead, age, dietary calcium intake, daily energy intake, and trimester of pregnancy).</p></caption><graphic xlink:href="ehp-117-26f3"></graphic></fig><table-wrap id="t1-ehp-117-26" position="float"><label>Table 1</label><caption><p>Baseline characteristics of participants, by treatment assignment and follow-up status.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th colspan="2" align="center" rowspan="1">Treatment assignment
<hr></hr></th><th colspan="2" align="center" rowspan="1">Follow-up status
<hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Calcium (<italic>n</italic> = 334)</th><th align="center" rowspan="1" colspan="1">Placebo (<italic>n</italic> = 336)</th><th align="center" rowspan="1" colspan="1">Completed<xref ref-type="table-fn" rid="tfn2-ehp-117-26">a</xref> (<italic>n</italic> = 565)</th><th align="center" rowspan="1" colspan="1">Lost (<italic>n</italic> = 105)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">26.9 ± 5.6</td><td align="center" rowspan="1" colspan="1">25.9 ± 5.3<xref ref-type="table-fn" rid="tfn3-ehp-117-26">b</xref></td><td align="center" rowspan="1" colspan="1">26.5 ± 5.5</td><td align="center" rowspan="1" colspan="1">26.2 ± 5.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (years)</td><td align="center" rowspan="1" colspan="1">10.8 ± 2.9</td><td align="center" rowspan="1" colspan="1">10.6 ± 2.9</td><td align="center" rowspan="1" colspan="1">10.7 ± 2.9</td><td align="center" rowspan="1" colspan="1">10.7 ± 2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">No. of pregnancies</td><td align="center" rowspan="1" colspan="1">2.0 ± 1.0</td><td align="center" rowspan="1" colspan="1">2.1 ± 1.1</td><td align="center" rowspan="1" colspan="1">2.1 ± 1.1</td><td align="center" rowspan="1" colspan="1">2.0 ± 0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">61.9 ± 10.7</td><td align="center" rowspan="1" colspan="1">61.5 ± 10.0</td><td align="center" rowspan="1" colspan="1">61.6 ± 10.2</td><td align="center" rowspan="1" colspan="1">62.2 ± 11.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">154.4 ± 5.6</td><td align="center" rowspan="1" colspan="1">154.4 ± 5.9</td><td align="center" rowspan="1" colspan="1">154.3 ± 5.8</td><td align="center" rowspan="1" colspan="1">155.0 ± 5.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Dietary calcium intake (g/day)</td><td align="center" rowspan="1" colspan="1">0.92 ± 0.35</td><td align="center" rowspan="1" colspan="1">0.89 ± 0.40</td><td align="center" rowspan="1" colspan="1">0.90 ± 0.38</td><td align="center" rowspan="1" colspan="1">0.94 ± 0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Total energy intake (kcal/day)</td><td align="center" rowspan="1" colspan="1">2,213 ± 632</td><td align="center" rowspan="1" colspan="1">2,157 ± 675</td><td align="center" rowspan="1" colspan="1">2,155 ± 642</td><td align="center" rowspan="1" colspan="1">2,347 ± 699<xref ref-type="table-fn" rid="tfn3-ehp-117-26">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Current use of LGC [no. (%)]</td><td align="center" rowspan="1" colspan="1">117 (35%)</td><td align="center" rowspan="1" colspan="1">115 (34%)</td><td align="center" rowspan="1" colspan="1">205 (36%)</td><td align="center" rowspan="1" colspan="1">27 (26%)<xref ref-type="table-fn" rid="tfn3-ehp-117-26">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Blood lead (μg/dL)<xref ref-type="table-fn" rid="tfn4-ehp-117-26">c</xref></td><td align="center" rowspan="1" colspan="1">3.8 (2.0)</td><td align="center" rowspan="1" colspan="1">4.1 (2.0)</td><td align="center" rowspan="1" colspan="1">3.8 (2.0)</td><td align="center" rowspan="1" colspan="1">4.5 (1.9)</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-ehp-117-26"><p>Values are mean ± SD except where noted.</p></fn><fn id="tfn2-ehp-117-26"><label>a</label><p>Completed follow-up defined as having at least one follow-up blood lead level at 6 or 8 months of pregnancy.</p></fn><fn id="tfn3-ehp-117-26"><label>b</label><p><italic>p</italic> &lt; 0.05 Student’s <italic>t</italic>-test or Wilcoxon rank-sum (Mann–Whitney <italic>U</italic>-test) two-sample test of equality for difference in means or chi-square test, as appropriate.</p></fn><fn id="tfn4-ehp-117-26"><label>c</label><p>Geometric mean (geometric standard deviation) blood lead levels.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ehp-117-26" position="float"><label>Table 2</label><caption><p>Effect of calcium supplementation on blood lead concentration (log-transformed) (<italic>n</italic> = 557; intent-to-treat analysis).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">β-Coefficient</th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Treatment (calcium = 1; placebo = 0)</td><td align="center" rowspan="1" colspan="1">−0.117</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">(−0.196 to −0.038)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood lead at baseline (μg/dL)<xref ref-type="table-fn" rid="tfn5-ehp-117-26">a</xref></td><td align="center" rowspan="1" colspan="1">0.674</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">(0.165 to 0.732)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.051</td><td align="center" rowspan="1" colspan="1">(−0.00003 to 0.014)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dietary calcium intake at baseline (g/day)</td><td align="center" rowspan="1" colspan="1">−0.024</td><td align="center" rowspan="1" colspan="1">0.751</td><td align="center" rowspan="1" colspan="1">(−0.169 to 0.122)</td></tr><tr><td align="left" rowspan="1" colspan="1">Total energy intake at baseline (1,000 kcal/day)</td><td align="center" rowspan="1" colspan="1">−0.010</td><td align="center" rowspan="1" colspan="1">0.813</td><td align="center" rowspan="1" colspan="1">(−0.096 to 0.075)</td></tr><tr><td align="left" rowspan="1" colspan="1">Trimester of pregnancy (time: 1 = third; 0 = second)</td><td align="center" rowspan="1" colspan="1">0.119</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">(0.073 to 0.166)</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-ehp-117-26"><label>a</label><p>Log-transformed outcome variable, thus estimate of treatment effect: 1 − <italic>e</italic><sup>−0.117</sup> = −11% (95% CI, −17.8% to −3.7%).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ehp-117-26" position="float"><label>Table 3</label><caption><p>Effect of calcium supplementation<xref ref-type="table-fn" rid="tfn6-ehp-117-26">a</xref> by treatment compliance.<xref ref-type="table-fn" rid="tfn7-ehp-117-26">b</xref></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"></th><th colspan="3" align="center" rowspan="1">Average (Overall)
<hr></hr></th><th colspan="3" align="center" rowspan="1">Second trimester
<hr></hr></th><th colspan="3" align="center" rowspan="1">Third trimester
<hr></hr></th></tr><tr><th align="left" rowspan="1" colspan="1">Compliance</th><th align="center" rowspan="1" colspan="1">No.</th><th align="center" rowspan="1" colspan="1">β</th><th align="center" rowspan="1" colspan="1">% Δ<xref ref-type="table-fn" rid="tfn8-ehp-117-26">c</xref></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" rowspan="1" colspan="1">β</th><th align="center" rowspan="1" colspan="1">%Δ<xref ref-type="table-fn" rid="tfn8-ehp-117-26">c</xref></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th><th align="center" rowspan="1" colspan="1">β</th><th align="center" rowspan="1" colspan="1">%Δ<xref ref-type="table-fn" rid="tfn8-ehp-117-26">c</xref></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">All</td><td align="center" rowspan="1" colspan="1">557</td><td align="center" rowspan="1" colspan="1">−0.12</td><td align="center" rowspan="1" colspan="1">−11%</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">−0.15</td><td align="center" rowspan="1" colspan="1">−14%</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">−0.08</td><td align="center" rowspan="1" colspan="1">−8%</td><td align="center" rowspan="1" colspan="1">0.107</td></tr><tr><td align="left" rowspan="1" colspan="1">&lt; 50%</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1">20%</td><td align="center" rowspan="1" colspan="1">0.115</td><td align="center" rowspan="1" colspan="1">0.30</td><td align="center" rowspan="1" colspan="1">35%</td><td align="center" rowspan="1" colspan="1">0.024</td><td align="center" rowspan="1" colspan="1">0.09</td><td align="center" rowspan="1" colspan="1">9%</td><td align="center" rowspan="1" colspan="1">0.497</td></tr><tr><td align="left" rowspan="1" colspan="1">≤ 50%</td><td align="center" rowspan="1" colspan="1">475</td><td align="center" rowspan="1" colspan="1">−0.17</td><td align="center" rowspan="1" colspan="1">−15%</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">−0.22</td><td align="center" rowspan="1" colspan="1">−20%</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">−0.11</td><td align="center" rowspan="1" colspan="1">−10%</td><td align="center" rowspan="1" colspan="1">0.037</td></tr><tr><td align="left" rowspan="1" colspan="1">≤ 67%</td><td align="center" rowspan="1" colspan="1">357</td><td align="center" rowspan="1" colspan="1">−0.20</td><td align="center" rowspan="1" colspan="1">−19%</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">−0.28</td><td align="center" rowspan="1" colspan="1">−24%</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">−0.12</td><td align="center" rowspan="1" colspan="1">−11%</td><td align="center" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">≤ 75%</td><td align="center" rowspan="1" colspan="1">241</td><td align="center" rowspan="1" colspan="1">−0.27</td><td align="center" rowspan="1" colspan="1">−24%</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">−0.32</td><td align="center" rowspan="1" colspan="1">−27%</td><td align="center" rowspan="1" colspan="1">&lt; 0.001</td><td align="center" rowspan="1" colspan="1">−0.21</td><td align="center" rowspan="1" colspan="1">−19%</td><td align="center" rowspan="1" colspan="1">0.004</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-ehp-117-26"><label>a</label><p>Adjusted for baseline blood lead level, maternal age, dietary calcium intake at baseline, daily energy intake at baseline, treatment group, and trimester of pregnancy.</p></fn><fn id="tfn7-ehp-117-26"><label>b</label><p>We assessed compliance by pill count at each visit and analyzed it as proportion of expected pills used between baseline (first trimester) and end of follow-up (8 months’ gestation).</p></fn><fn id="tfn8-ehp-117-26"><label>c</label><p>Percent change; log-transformed outcome variable, thus estimate of treatment effect: 1 − e<sup>−β</sup>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ehp-117-26" position="float"><label>Table 4</label><caption><p>Effect of calcium supplementation<xref ref-type="table-fn" rid="tfn9-ehp-117-26">a</xref> by baseline blood lead level.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Baseline blood lead level</th><th align="center" rowspan="1" colspan="1">No. (calcium/placebo)</th><th align="center" rowspan="1" colspan="1">β-Coefficient</th><th align="center" rowspan="1" colspan="1">%Δ<xref ref-type="table-fn" rid="tfn10-ehp-117-26">b</xref></th><th align="center" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td colspan="5" align="left" rowspan="1">Among all women with follow-up (intent-to-treat analysis)</td></tr><tr><td align="left" rowspan="1" colspan="1"> &lt; 5 μg/dL</td><td align="center" rowspan="1" colspan="1">349 (183/166)</td><td align="center" rowspan="1" colspan="1">−0.07</td><td align="center" rowspan="1" colspan="1">−7%</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1"> ≥ 5 μg/dL</td><td align="center" rowspan="1" colspan="1">208 (100/108)</td><td align="center" rowspan="1" colspan="1">−0.19</td><td align="center" rowspan="1" colspan="1">−17%</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="5" align="left" rowspan="1">Among those women with compliance ≥ 50%<xref ref-type="table-fn" rid="tfn11-ehp-117-26">c</xref> (as-treated analysis, among high compliers)</td></tr><tr><td align="left" rowspan="1" colspan="1"> &lt; 5 μg/dL</td><td align="center" rowspan="1" colspan="1">292 (162/130)</td><td align="center" rowspan="1" colspan="1">−0.15</td><td align="center" rowspan="1" colspan="1">−14%</td><td align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">  ≥5 μg/dL</td><td align="center" rowspan="1" colspan="1">183 (87/96)</td><td align="center" rowspan="1" colspan="1">−0.19</td><td align="center" rowspan="1" colspan="1">−17%</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td colspan="5" align="left" rowspan="1">Among those women with compliance &lt; 50%<xref ref-type="table-fn" rid="tfn11-ehp-117-26">c</xref> (as-treated analysis, among low compliers)</td></tr><tr><td align="left" rowspan="1" colspan="1"> &lt; 5 μg/dL</td><td align="center" rowspan="1" colspan="1">57 (21/36)</td><td align="center" rowspan="1" colspan="1">0.29</td><td align="center" rowspan="1" colspan="1">34%</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">  ≥5 μg/dL</td><td align="center" rowspan="1" colspan="1">25 (13/12)</td><td align="center" rowspan="1" colspan="1">−0.18</td><td align="center" rowspan="1" colspan="1">−17%</td><td align="left" rowspan="1" colspan="1">0.49</td></tr></tbody></table><table-wrap-foot><fn id="tfn9-ehp-117-26"><label>a</label><p>Adjusting for baseline blood lead level (log-transformed), maternal age, dietary calcium intake at baseline, daily energy intake at baseline, treatment group, and trimester of pregnancy.</p></fn><fn id="tfn10-ehp-117-26"><label>b</label><p>Percent change; log-transformed outcome variable, thus estimate of treatment effect: 1 − <italic>e</italic><sup>−β</sup>.</p></fn><fn id="tfn11-ehp-117-26"><label>c</label><p>We assessed compliance by pill count at each visit and analyzed as proportion of expected pills used between baseline (first trimester) and end of follow-up (8 months’ gestation).</p></fn></table-wrap-foot></table-wrap></floats-group></article>